Sign in
Taking people in United StatesPhase 3

Zoldonrasib and daraxonrasib versus chemotherapy for first treatment of metastatic KRAS G12D pancreatic cancer

Compares zoldonrasib with daraxonrasib against chemotherapy in newly treated metastatic KRAS G12D pancreatic cancer.

Key facts

Who runs it
Revolution Medicines, Inc.
Where
Jacksonville, Phoenix, Providence, Rochester, Scottsdale, and Tampa, United StatesSee the 6 sites
Trial code
Registry title
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Status
Recruiting
Phase
Phase 3
People taking part
400 people, planned
Started
28 Aug 2026
Expected to end
Apr 2030
Type of study
Interventional, 2 groups
Treatments tested
  • daraxonrasib
  • gemcitabine
  • nab-paclitaxel
  • zoldonrasib
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with metastatic pancreatic adenocarcinoma with a KRAS G12D mutation who have not yet had treatment for advanced disease.

Age
18 years or older
Sex
All sexes can join
Disease stage
Pancreatic adenocarcinoma (including adenosquamous carcinoma) that has spread (metastatic), diagnosed as metastatic no more than 6 weeks before consent, with disease that can be measured (RECIST v1.1).
Earlier treatment
No earlier treatment for locally advanced unresectable or metastatic disease. No earlier MAPK-pathway targeted therapy or RAS-targeted vaccine in the metastatic setting.
Biomarker or test result
A documented KRAS G12D mutation.

Main reasons for not taking part

  • Known driver mutations that have approved targeted therapies
  • Acinar cell carcinoma, pancreatic neuroendocrine tumors or other non-adenocarcinoma pancreatic cancers
  • Active or known untreated cancer spread to the brain or its linings (central nervous system or leptomeningeal disease)
  • Conditions that affect taking or absorbing the study drug
  • Major surgery within 28 days before randomization

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • At least 18 years old and has provided informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally advanced unresectable or metastatic setting
  • No prior treatment in the locally advanced unresectable or metastatic setting
  • Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent
  • Documented KRAS G12D mutation status
  • Measurable disease per RECIST v1.1
  • Adequate organ function (bone marrow, liver, kidney, coagulation)

Who cannot take part

  • Mutation status with known driver mutations for which there are approved targeted therapies
  • Prior treatment with MAPK-pathway targeted therapy or administration of RAS-targeted vaccine in the metastatic setting
  • Major surgery within 28 days prior to randomization
  • Acinar cell carcinoma, pancreatic neuroendocrine tumors, tumors involving islet cells or islet cell neoplasms, and other non-adenocarcinoma pancreatic malignancies
  • Active or known history of untreated central nervous system metastatic or leptomeningeal disease
  • Any conditions that may affect the ability to take or absorb study drug
  • Tumors determined to originate from non-pancreatic primary sites
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures
  • Additional inclusion \& exclusion criteria may apply

Where in United States

  • Mayo Clinic FloridaJacksonville, United StatesContact: Hani M. BabikerTaking people
  • Mayo Clinic - ArizonaPhoenix, United StatesContact: Tanios S. Bekaii-SaabTaking people
  • Rhode Island HospitalProvidence, United StatesContact: Andrew SchumacherTaking people
  • Mayo Clinic - RochesterRochester, United StatesContact: Ben GeorgeTaking people
  • HonorHealth Research InstituteScottsdale, United StatesContact: Amy MalensekTaking people
  • Moffitt Cancer CenterTampa, United StatesContact: Cheyenne SchneiderTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

The 2 groups in the trial

  • Arm A: daraxonrasib + zoldonrasibTreatment being tested

    combination of study drugs

    Treatment: daraxonrasib and zoldonrasib

  • Arm B: gemcitabine and nab-paclitaxelTreatment being tested

    chemotherapy

    Treatment: gemcitabine and nab-paclitaxel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Plain-language title
Zoldonrasib and daraxonrasib versus chemotherapy for first treatment of metastatic KRAS G12D pancreatic cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2026